par Baselga, José;Bradbury, Ian;Eidtmann, Holger;Di Cosimo, Serena;de Azambuja, Evandro 
;Aura, Claudia Monica;Gomez, Henry;Dinh, Phuong ;Fauria, Karine;van Dooren, Veerle;Aktan, Gursel;Goldhirsch, Aron;Chang, Tsai-Wang;Horváth, Zsolt;Coccia-Portugal, Maria;Domont, Julien;Tseng, Ling-Min;Kunz, Georg;Sohn, Joo Hyuk;Semiglazov, Vladimir;Lerzo, Guillermo;Palacova, Marketa;Probachai, Volodymyr;Pusztai, Lajos;Untch, Michael;Gelber, Richard;Piccart-Gebhart, Martine ;NeoALTTO Study Team,
Référence Lancet, 379, 9816, page (633-640)
Publication Publié, 2012-02
;Aura, Claudia Monica;Gomez, Henry;Dinh, Phuong ;Fauria, Karine;van Dooren, Veerle;Aktan, Gursel;Goldhirsch, Aron;Chang, Tsai-Wang;Horváth, Zsolt;Coccia-Portugal, Maria;Domont, Julien;Tseng, Ling-Min;Kunz, Georg;Sohn, Joo Hyuk;Semiglazov, Vladimir;Lerzo, Guillermo;Palacova, Marketa;Probachai, Volodymyr;Pusztai, Lajos;Untch, Michael;Gelber, Richard;Piccart-Gebhart, Martine ;NeoALTTO Study Team, Référence Lancet, 379, 9816, page (633-640)
Publication Publié, 2012-02
Article révisé par les pairs
| Résumé : | The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy. |
